By: IPP Bureau
Last updated : September 25, 2026 9:12 am
Fully automated, multiplex autoantibody detection solution, enabling population-wide screening programs
Revvity has launched the GSP T1D 3plex kit, a fully automated, CE-IVDR-certified screening tool designed to detect type 1 diabetes (T1D) autoantibodies in children before symptoms appear. By utilizing an automated, multiplex approach, the solution enables large-scale, population-wide screening initiatives to identify at-risk youth early.
Type 1 diabetes (T1D) poses a major public health challenge because it is rarely diagnosed until extensive pancreatic beta-cell damage triggers a life-threatening episode of diabetic ketoacidosis (DKA).
To address this, Revvity's GSP T1D 3plex kit offers an all-in-one screening system—combining reagents, hardware, and specialized software—built on a highly trusted, automated newborn testing platform. By analyzing simple capillary dried blood spots (DBS), this scalable workflow detects high-risk individuals months or even years before symptoms appear, paving the way for proactive care and early, disease-modifying treatments.
"The launch of the GSP T1D 3plex kit marks an important step forward for Revvity’s expansion into child health screening,” said Anna Godenhjelm, vice president and general manager of reproductive health at Revvity. “This milestone demonstrates how our expertise in newborn screening can be leveraged to advance earlier detection in new areas of healthcare."
The GSP T1D 3plex kit is designed to meet the needs of emerging national T1D screening programs, providing a reliable, regulatory-compliant solution. It is the latest addition to Revvity's expanding diabetes portfolio, which spans research, clinical testing and service models.
At the European Association for the Study of Diabetes (EASD) in Milan, Italy, from September 28 – October 2, Revvity will be presenting details on both its T1D on-site installation and off-site testing service solutions developed in collaboration with Sanofi.
The GSP T1D 3plex kit will initially be available in Europe and all markets that accept CE IVD-marked products. The GSP T1D 3plex is not a U.S. Food and Drug Administration (FDA)-cleared device.